Seres Therapeutics (MCRB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.46, -2.77% vs the prior close of $2.53.
- Volume 38.57K shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MCRB dips 2.8% to $2.46. Closed at $2.46, -2.77% vs the prior close of $2.53. Day range $2.42–$2.56, opened at $2.56.
MCRB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MCRB dips 2.8% to $2.46
- Closed at $2.46, -2.77% vs the prior close of $2.53. Day range $2.42–$2.56, opened at $2.56.
- Volume was 38.57K shares, 0.6x its 50-day average of 66.90K — lighter than usual.
- Price is -40.5% vs its 50-day average ($4.13) and -68.4% vs its 200-day average ($7.78).
- 52-week range $2.38–$29.98; today's close sits at 0% of that range, 91.8% below the 52-week high.
Oct 15, 2026 — MCRB jumps 4.5% to $2.53
- Closed at $2.53, +4.55% vs the prior close of $2.42. Day range $2.40–$2.61, opened at $2.40.
- Volume was 24.60K shares, 0.4x its 50-day average of 69.24K — lighter than usual.
- Price is -39.5% vs its 50-day average ($4.18) and -67.7% vs its 200-day average ($7.84).
- 52-week range $2.38–$29.98; today's close sits at 1% of that range, 91.6% below the 52-week high.
Oct 14, 2026 — MCRB slides 4.3% to $2.42, a 52-week low, 3 down days in a row
- Closed at $2.42, -4.35% vs the prior close of $2.53. Day range $2.38–$2.66, opened at $2.65.
- Volume was 41.90K shares, 0.6x its 50-day average of 69.21K.
- Price is -42.8% vs its 50-day average ($4.23) and -69.4% vs its 200-day average ($7.90).
- 52-week range $2.38–$29.98; today's close sits at 0% of that range, 91.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — MCRB slides 5.6% to $2.53, a 52-week low
- Closed at $2.53, -5.60% vs the prior close of $2.68. Day range $2.51–$2.66, opened at $2.66.
- Volume was 44.10K shares, 0.6x its 50-day average of 68.92K.
- Price is -41.0% vs its 50-day average ($4.29) and -68.2% vs its 200-day average ($7.96).
- 52-week range $2.42–$29.98; today's close sits at 0% of that range, 91.6% below the 52-week high.
Oct 12, 2026 — MCRB dips 1.1% to $2.68
- Closed at $2.68, -1.11% vs the prior close of $2.71. Day range $2.66–$2.78, opened at $2.75.
- Volume was 54.30K shares, 0.8x its 50-day average of 68.86K.
- Price is -38.2% vs its 50-day average ($4.34) and -66.6% vs its 200-day average ($8.03).
- 52-week range $2.42–$29.98; today's close sits at 1% of that range, 91.1% below the 52-week high.
Oct 9, 2026 — MCRB jumps 3.0% to $2.71
- Closed at $2.71, +3.04% vs the prior close of $2.63. Day range $2.58–$2.75, opened at $2.65.
- Volume was 79.40K shares, 1.2x its 50-day average of 68.28K.
- Price is -38.1% vs its 50-day average ($4.38) and -66.5% vs its 200-day average ($8.09).
- 52-week range $2.42–$29.98; today's close sits at 1% of that range, 91.0% below the 52-week high.
Oct 8, 2026 — MCRB slides 3.3% to $2.63, a 52-week low on 3.3x normal volume
- Closed at $2.63, -3.31% vs the prior close of $2.72. Day range $2.42–$2.72, opened at $2.68.
- Volume was 213.40K shares, 3.3x its 50-day average of 65.08K — unusually heavy trading.
- Price is -40.5% vs its 50-day average ($4.42) and -67.7% vs its 200-day average ($8.15).
- 52-week range $2.42–$29.98; today's close sits at 1% of that range, 91.2% below the 52-week high.
Oct 7, 2026 — MCRB slides 6.2% to $2.72, a 52-week low
- Closed at $2.72, -6.21% vs the prior close of $2.90. Day range $2.70–$3.00, opened at $2.86.
- Volume was 60.40K shares, 0.9x its 50-day average of 65.14K.
- Price is -39.0% vs its 50-day average ($4.46) and -66.9% vs its 200-day average ($8.21).
- 52-week range $2.70–$29.98; today's close sits at 0% of that range, 90.9% below the 52-week high.
Oct 6, 2026 — MCRB rises 1.8% to $2.90
- Closed at $2.90, +1.75% vs the prior close of $2.85. Day range $2.80–$3.02, opened at $2.88.
- Volume was 76.40K shares, 1.2x its 50-day average of 64.96K.
- Price is -35.6% vs its 50-day average ($4.50) and -64.9% vs its 200-day average ($8.27).
- 52-week range $2.80–$29.98; today's close sits at 0% of that range, 90.3% below the 52-week high.
Oct 5, 2026 — MCRB slides 3.1% to $2.85, a 52-week low
- Closed at $2.85, -3.06% vs the prior close of $2.94. Day range $2.81–$2.91, opened at $2.91.
- Volume was 63.30K shares, 1.0x its 50-day average of 65.38K.
- Price is -37.2% vs its 50-day average ($4.54) and -65.8% vs its 200-day average ($8.34).
- 52-week range $2.81–$29.98; today's close sits at 0% of that range, 90.5% below the 52-week high.
Oct 2, 2026 — MCRB rises 0.3% to $2.94
- Closed at $2.94, +0.34% vs the prior close of $2.93. Day range $2.91–$3.20, opened at $2.98.
- Volume was 100.70K shares, 1.6x its 50-day average of 63.97K.
- Price is -35.9% vs its 50-day average ($4.58) and -65.0% vs its 200-day average ($8.40).
- 52-week range $2.83–$29.98; today's close sits at 0% of that range, 90.2% below the 52-week high.
MCRB latest news & SEC filings
Every SEC filing by or about MCRB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 21, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Brady Kelly sold 64 shares at $4.55 (≈$291) on Aug 17, 2026
- Brady Kelly sold 64 shares at $4.55 (≈$291) on Aug 17, 2026
- Brady Kelly sold 64 shares at $4.55 (≈$291) on Aug 17, 2026
- Brady Kelly sold 64 shares at $4.55 (≈$291) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shaff Eric D. sold 263 shares at $4.55 (≈$1.20K) on Aug 17, 2026
- Shaff Eric D. sold 263 shares at $4.55 (≈$1.20K) on Aug 17, 2026
- Shaff Eric D. sold 263 shares at $4.55 (≈$1.20K) on Aug 17, 2026
- Shaff Eric D. sold 263 shares at $4.55 (≈$1.20K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Henn Matthew R sold 81 shares at $4.55 (≈$369) on Aug 17, 2026
- Henn Matthew R sold 81 shares at $4.55 (≈$369) on Aug 17, 2026
- Henn Matthew R sold 81 shares at $4.55 (≈$369) on Aug 17, 2026
- Henn Matthew R sold 81 shares at $4.55 (≈$369) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Desrosier Thomas sold 82 shares at $4.55 (≈$373) on Aug 17, 2026
- Desrosier Thomas sold 82 shares at $4.55 (≈$373) on Aug 17, 2026
- Desrosier Thomas sold 82 shares at $4.55 (≈$373) on Aug 17, 2026
- Desrosier Thomas sold 82 shares at $4.55 (≈$373) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $736.00K (prior year $0)
- Net income: $4.58M (prior year -$19.86M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.47 (prior year -$2.27) (swung to profit vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
Aug 4, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 9, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Jul 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade MCRB
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 12, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.47% (largest 12.5%). That is a volatile stock.
- Liquidity: about 74.85K shares (≈$184.13K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.46 vs a range of $2.38–$29.98 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Apr 22, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Matthew R Henn sold 81 shares on Aug 17, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Aug 4, 2026.
- Share count: 9.94M shares outstanding (Aug 3, 2026), +13.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MCRB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.56 | 2.56 | 2.42 | 2.46 | 38.57K |
| Oct 15, 2026 | 2.40 | 2.61 | 2.40 | 2.53 | 24.60K |
| Oct 14, 2026 | 2.65 | 2.66 | 2.38 | 2.42 | 41.90K |
| Oct 13, 2026 | 2.66 | 2.66 | 2.51 | 2.53 | 44.10K |
| Oct 12, 2026 | 2.75 | 2.78 | 2.66 | 2.68 | 54.30K |
| Oct 9, 2026 | 2.65 | 2.75 | 2.58 | 2.71 | 79.40K |
| Oct 8, 2026 | 2.68 | 2.72 | 2.42 | 2.63 | 213.40K |
| Oct 7, 2026 | 2.86 | 3.00 | 2.70 | 2.72 | 60.40K |
| Oct 6, 2026 | 2.88 | 3.02 | 2.80 | 2.90 | 76.40K |
| Oct 5, 2026 | 2.91 | 2.91 | 2.81 | 2.85 | 63.30K |
| Oct 2, 2026 | 2.98 | 3.20 | 2.91 | 2.94 | 100.70K |
| Oct 1, 2026 | 3.10 | 3.41 | 2.83 | 2.93 | 247.30K |
| Sep 30, 2026 | 3.47 | 3.49 | 3.26 | 3.35 | 54.60K |
| Sep 29, 2026 | 3.54 | 3.59 | 3.35 | 3.48 | 71.20K |
| Sep 28, 2026 | 3.49 | 3.55 | 3.40 | 3.52 | 55.50K |
| Sep 25, 2026 | 3.66 | 3.69 | 3.50 | 3.52 | 55.60K |
| Sep 24, 2026 | 3.71 | 3.85 | 3.52 | 3.62 | 89.60K |
| Sep 23, 2026 | 4.06 | 4.22 | 3.73 | 3.79 | 51.60K |
| Sep 22, 2026 | 4.13 | 4.15 | 3.93 | 4.02 | 35.70K |
| Sep 21, 2026 | 4.23 | 4.33 | 3.90 | 4.07 | 38.80K |
About Seres Therapeutics
Seres Therapeutics (MCRB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1609809.
MCRB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dennis A Ausiello | Director | Jul 10, 2026 |
| Stephen Berenson | Director | Jul 10, 2026 |
| Willard H Dere | Director | Jul 10, 2026 |
| Claire Fraser | Director | Jul 10, 2026 |
| Kurt Graves | Director | Jul 10, 2026 |
| Richard N Kender | See Remarks | Jul 10, 2026 |
| Robert L. Rosiello | Director | Jul 10, 2026 |
| Eric D. Shaff | Director | Aug 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kelly Brady | See Remarks | Aug 18, 2026 |
| Thomas Desrosier | See Remarks | Aug 18, 2026 |
| Matthew R Henn | See Remarks | Aug 18, 2026 |
| Richard N Kender | See Remarks | Jul 10, 2026 |
| Marella Thorell | See Remarks | Jul 10, 2026 |
| Teresa L. Young | See Remarks | Feb 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Matthew R Henn | Sale | 81 | $4.55 |
| Aug 17, 2026 | Matthew R Henn | Sale | 81 | $4.55 |
| Aug 17, 2026 | Matthew R Henn | Sale | 81 | $4.55 |
| Aug 17, 2026 | Matthew R Henn | Sale | 81 | $4.55 |
| Aug 17, 2026 | Eric D. Shaff | Sale | 263 | $4.55 |
| Aug 17, 2026 | Eric D. Shaff | Sale | 263 | $4.55 |
| Aug 17, 2026 | Eric D. Shaff | Sale | 263 | $4.55 |
| Aug 17, 2026 | Eric D. Shaff | Sale | 263 | $4.55 |
| Aug 17, 2026 | Thomas Desrosier | Sale | 82 | $4.55 |
| Aug 17, 2026 | Thomas Desrosier | Sale | 82 | $4.55 |
| Aug 17, 2026 | Thomas Desrosier | Sale | 82 | $4.55 |
| Aug 17, 2026 | Thomas Desrosier | Sale | 82 | $4.55 |
| Aug 17, 2026 | Kelly Brady | Sale | 64 | $4.55 |
| Aug 17, 2026 | Kelly Brady | Sale | 64 | $4.55 |
| Aug 17, 2026 | Kelly Brady | Sale | 64 | $4.55 |
MCRB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $5.70M | 0.64 | $1.12M |
| Dec 31, 2024 | — | $136.00K | 0.00 | $-148.61M |
| Dec 31, 2023 | — | $-113.72M | -17.77 | $-117.35M |
| Dec 31, 2022 | $7.13M | $-250.16M | -2.31 | $-228.82M |
| Dec 31, 2021 | $143.86M | $-65.58M | -0.72 | $6.69M |
Latest balance sheet: total assets $101.59M, total liabilities $67.05M, cash $15.59M (as of Jun 30, 2026).
MCRB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $5.01 |
| May 5, 2026 | 8-K Item 2.02 (results) | $7.50 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $9.05 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $12.70 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $13.78 |
| May 7, 2025 | 8-K Item 2.02 (results) | $8.29 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $12.76 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $16.88 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $11.80 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 5, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MCRB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.